FindMyKOL
Clinical trialNCT06571045Active, not recruitingPhase 2/PHASE3Interventional

A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME

SponsorEyeBiotech Ltd.Enrollment984Diabetic Macular Edema (DME)
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of remigromig (EYE103) in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME) In the first year, all 3 treatment groups will be treated every 4 weeks with either remigromig or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm. Approximately 960 participants will be entered in the study.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

183 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Argentina
  • Buenos Aires, Argentina

    CABA, Buenos Aires, Argentina

  • Buenos Aires, Argentina

    CABA, Buenos Aires, Argentina

  • Buenos Aires, Argentina

    CABA, Buenos Aires, Argentina

  • Caba, Buenos Aires, Argentina

    Caba, Buenos Aires, Argentina

  • Cordoba, Argentina

    Córdoba, Córdoba Province, Argentina

  • Santa Fe, Argentina

    Rosario, Santa Fe Province, Argentina

  • Santa Fe, Argentina

    Rosario, Sante Fe, Argentina

  • Buenos Aires, Argentina

    CABA, Argentina

  • Ciudad de Cordoba, Argentina

    Córdoba, Argentina

Australia
  • Sydney Retina Clinic

    Sydney, New South Wales, Australia

  • Sydney, Australia

    Sydney, New South Wales, Australia

  • Albury, Australia

    Albury, Australia

  • Parramatta, Australia

    Parramatta, Australia

  • Sydney, Australia

    Sydney, Australia

Austria
  • Graz, Austria

    Graz, Austria

  • Innsbruck, Austria

    Innsbruck, Austria

  • Vienna, Austria

    Vienna, Austria

  • Vienna, Austria

    Vienna, Austria

Colombia
  • Medellin, Colombia

    Medellín, Antioquia, Colombia

  • Barranquilla, Colombia

    Barranquilla, Atlántico, Colombia

  • Bogota, Columbia

    Bogotá, Columbia, Colombia

  • Cali, Colombia

    Cali, Valle del Cauca Department, Colombia

  • Medellin, Colombia

    Medellín, Colombia

Croatia
  • Osijek, Croatia

    Osijek, Croatia

Czechia
  • Mlada Boleslav, Czechia

    Mladá Boleslav, Czechia

  • Nachod, Czechia

    Náchod, Czechia

  • Prague, Czechia

    Prague, Czechia

  • Prague, Czechia

    Prague, Czechia

France
  • Cedex, France

    Dijon, Cedex, France

  • Creteil, France

    Créteil, France

  • Lyon, France

    Lyon, France

  • Marseille, France

    Marseille, France

  • Paris, France

    Paris, France

  • Paris, France

    Paris, France

  • Paris, France

    Paris, France

  • Saint Cyr Sur Loire, France

    Saint-Cyr-sur-Loire, France

Germany
  • Frankfurt, Germany

    Frankfurt, Germany

  • Hanover, Germany

    Hanover, Germany

  • Munchen, Germany

    München, Germany

  • Munster, Germany

    Münster, Germany

143 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Ranibizumab →Remigromig
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
7 Aug 2024
Primary completion
14 Jul 2026
Completion
31 Dec 2027
Last update posted
14 Oct 2026
Registered enrollment
984
Registry id
NCT06571045
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.